Introduction
The c-kit (CD117) proto-oncogene encodes a transmembrane tyrosine kinase receptor that is structurally related to the platelet-derived growth factor receptor (Vandenbark et al., 1992; Yarden et al., 1987) . Upon binding of the KIT ligand (also known as stem cell factor; steel factor and mast cell growth factor), the KIT receptor initiates a signal transduction phosphorylation cascade, resulting in the regulation of cell growth (Brizzi et al., 1994; Funasaka et al., 1992) . KIT is known to play a role in the development of melanocytes, germ cells, and several precursors to hematopoietic cells, including mast cells (Vliagoftis et al., 1997) . In adult humans, KIT expression has been reported in a variety of normal tissues (Arber et al., 1998; Horie et al., 1993; Lammie et al., 1994; Matsuda et al., 1993; Tsuura et al., 1994) and in certain malignancies (Arber et al., 1998; Matsuda et al., 1993; Tsuura et al., 1994) .
It has recently been discovered that KIT plays a crucial role in the development and activity of the interstitial cells of Cajal (ICC). ICC arise from mesenchymal cells and form a network beginning at the level of the Auerbach's nerve plexus during development of the mammalian gastrointestinal tract. These cells are responsible for the`pacemaker activity' of intrinsic contraction of the intestinal smooth muscle (Sanders, 1996) . KIT has been shown to be present in ICC both during development and in mature tissue, but is not present in any other mesenchymal cells of the intestines (Kluppel et al., 1998; Torihashi et al., 1997) . Mice which are mutant for the murine homolog of the human c-kit gene are de®cient in ICC and lack intestinal pacemaker activity (Huizinga et al., 1995; Kluppel et al., 1998; Ward et al., 1994) . Humans with certain forms of intestinal motility disorders have been found to have alterations in the number and arrangement of ICC (Isozaki et al., 1997; Kenny et al., 1998; Vanderwinden et al., 1996a,b) .
The majority of gastrointestinal stromal tumors (GISTs) express KIT, suggesting that these tumors arise from ICC (Kindblom et al., 1998; Sarlomo-Rikala et al., 1998) . GISTs are classi®ed as gastrointestinal mesenchymal neoplasms without clear muscle or neural dierentiation. An initial study of six GISTs found that ®ve tumors contained gain of function mutations in the c-kit gene (Hirota et al., 1998) , presumably contributing to the molecular progression of these neoplasms. Each of the mutations was found in a contiguous stretch of 33 codons present in the juxtamembrane (JM) domain of the gene. Mesenchymal neoplasms of the gastrointestinal tract comprise a heterogeneous group, varying in histologic appearance, dierentiation patterns and clinical behavior. In order to more fully characterize the range of c-kit JM domain mutations in GISTs, we sequenced this gene segment from archival paran-embedded and frozen tissue samples of 56 mesenchymal gastrointestinal neoplasms that had been immunohistochemically analysed for KIT expression.
Results
The 56 neoplasms studied varied in the site of origin in the gastrointestinal tract, the expression of the myogenic protein desmin, and clinical behavior. The GISTs occurred in 24 men and 22 women; the age range was 30 ± 84 years (median 66). Twenty-one GISTs pursued a malignant clinical course, 14 followed a benign clinical course. There was inadequate follow-up for 11 GISTs whose malignant potential could not be established at the time of diagnosis. The leiomyomas occurred in four men and four women whose ages ranged from 15 ± 72 years (median 47). The leiomyosarcomas occurred in women with ages of 62 and 67 years, respectively.
Immunohistochemical analysis of gene expression revealed distinct dierences between tumor groups (Figure 1 ). Ninety-three per cent of GISTs were KIT positive, while 70% expressed CD34. None exhibited strong and diuse desmin protein expression. Leiomyomas and leiomyosarcomas uniformly were positive for desmin and negative for KIT and CD34.
After PCR ampli®cation and sequencing of the consensus mutation area of the c-kit JM domain, deviations from the wild-type sequence were found in nine GISTs (Figures 2 and 3) . The c-kit JM domain was PCR ampli®ed and sequenced from corresponding samples of normal tissue, revealing wild-type DNA sequence in all instances, verifying the somatic nature of the mutations in all cases (data not shown). In the tumors, the wild-type sequence was maintained in equal proportions to the mutant sequence (Figure 2 ), consistent with retention of the wild-type allele in the tumor cells.
One mutation was a non-conservative missense mutation (Val560Asp), ®ve were small deletions, resulting in the loss of 1 ± 19 codons which did not disrupt the downstream reading frame and one was an insertion of 12 codons which also did not disrupt the downstream reading frame (Figure 3 ). The insertion mutation consisted of a duplication of nucleotides 1722 ± 1754 of the c-kit open reading frame plus the addition of three more nucleotides, which results in the perfect tandem repeat of amino acids 575 ± 586 in the protein sequence.
Eight of the nine GISTs with c-kit JM mutations had at least one clinical parameter that predicted aggressive behavior (size 45 cm), mitotic rate greater than 5/50 high power microscopic ®elds) and each of the four tumors from patients with adequate follow-up did pursue a malignant clinical course.
Discussion
The tumor-speci®c c-kit mutations identi®ed in this study are similar to those previously reported, which are shown in functional studies to be constitutively activated (Hirota et al., 1998) . In the previous analysis, four of ®ve c-kit mutations were caused by small intragenic deletions in the JM domain that conserved the downstream reading frame. These ®ndings are in agreement with our results, in which six of the mutations consisted of similar small deletions. The single missense mutation in our tumor samples was a non-conservative change from valine to aspartic acid at position 560. The single missense mutation reported by Hirota et al. (1998) was an identical substitution at the adjacent position (Val559Asp, Figure 3) . Interestingly, the smallest deletion mutations found in both series also aect these paired valine residues. In the previous study the smallest intragenic mutation deleted both of these codons, while in our series 3 bp deletions removed one valine codon (Val560del) in two tumors, suggesting that this region in particular must be crucial for conformational changes required for normal Figure 3 Coding changes of c-kit JM domain mutations. The wild-type sequence of the c-kit JM domain is given in single character amino acid code at the top of the ®gure. The next eight sequences are mutations identi®ed in this study. The last ®ve sequences are from the original observation of c-kit mutations in GISTs (Hirota et al., 1998) . The most common form of mutation consists of intragenic deletions (shown as dashes) of 1 ± 19 codons that leave intact the downstream reading frame. Missense mutations (shown in bold italicized type) occur at the boundary of some deletions. The two missense mutations not associated with deletions are substitutions of aspartic acid for valine at adjacent residues. The insertion mutation is a duplication of 12 codons (see text for details) c-kit mutation in GISTs CA Moskaluk et al regulation of tyrosine kinase activity. These ®ndings suggest that there is a limited spectrum of missense mutations in the JM domain that activate KIT.
It is known that the wild-type KIT receptor tyrosine kinase, when not bound to its ligand, is present in an unphosphorylated monomer form on the cell surface. Upon binding of ligand, KIT dimerizes and becomes phosphorylated to form an enzymatically active complex. In the murine system, KIT proteins with missense mutations and deletions in the JM domain are constitutively active, and form dimers even in the absence of ligand (Kitayama et al., 1995; Tsujimura et al., 1996) . It is presumed that the alterations of the JM domain remove allosteric regulation of protein dimerization and enzymatic activity.
The ®nding in one of the GISTs in this study of a 12 codon insertion mutation is the ®rst description of a ckit insertion mutation found as a somatic change in a human neoplasm. The fact that it too conserves the downstream reading frame suggests that it disrupts an important regulatory domain but retains full catalytic activity, as has beeen shown to be the case for deletion mutations in this region.
The previous ®nding of c-kit JM domain mutations in ®ve of six GISTs suggested that the majority of these neoplasms would have acquired such alterations (Hirota et al., 1998) . Our survey of 46 GISTs provides no support for this prediction. Our sample of tumors represented the vast majority of all such neoplasms collected at our institution over a de®ned time period (Franquemont and Frierson, 1992) , and our high success rate in obtaining PCR products from this population makes a selection bias highly unlikely. In addition, our use of microdissection to enrich for tumor cells and direct cycle sequencing of PCR products makes false negative results unlikely. Although the categorization of GISTs remains somewhat controversial (Franquemont and Frierson, 1992; Hjermstad et al., 1987; Miettinen et al., 1995; Saul et al., 1987) , even when using conservative criteria and limiting the diagnosis of GIST to those neoplasms negative for diuse desmin expression and positive for KIT, only nine of 43 such tumors (21%) had c-kit JM domain mutations. Although the majority of mutations were found in tumors with malignant clinical behavior, our sample size was too small to make this ®nding statistically signi®cant.
There are other possible molecular mechanisms for KIT activation besides JM domain mutation. A mutation in other portions of the gene may also lead to activation, although this was not found in the initial small study of six tumors by RT ± PCR analysis (Hirota et al., 1998) . Since mutations in the phosphotransferase domain (exon 17) have been shown to occur in human mast cell neoplasms, this is an obvious candidate region to test in GISTs which do not contain JM domain mutations.
Other mechanisms leading to up-regulation of protooncogenes include an increase of wild-type gene expression. This may occur by promoter mutation or rearrangement or by an increase in gene copy number by DNA ampli®cation. The analysis of c-kit mRNA levels in fresh samples of GISTs with and without gene mutation will help elucidate the role (if any) that transcriptional activation plays in disregulation of KIT activity. It would also be helpful to perform in situ hybridization studies to determine if the c-kit gene is ampli®ed in neoplasms which do not contain mutations. Finally, it would be important to determine if the molecular mechanisms of KIT activation dier in the various neoplasms that show evidence of KIT protein expression.
Materials and methods

Case selection and collection of clinical data
Hematoxylin and eosin (H&E)-stained slides and formalin®xed paran-embedded blocks from 42 gastrointestinal stromal tumors (19 gastric, 15 small intestinal, eight colonic), seven leiomyomas (®ve esophageal, one gastric, one rectal) and two leiomyosarcomas (both colonic) were retrieved from the ®les of the Division of Surgical Pathology at the University of Virgina Health Sciences Center. Some of the details regarding the clinicopathologic features of the stromal tumors have been reported previously (Franquemont and Frierson, 1992) . Frozen specimens from four other gastric GISTs and one additional gastric leiomyoma were also available for study.
Mesenchymal neoplasms of the gastrointestinal tract were classi®ed as GISTs if they showed a lack of smooth muscle dierentiation by immunohistochemical evaluation. Tumors with characteristic interweaving fascicles of bland spindle cells which showed immunohistochemical evidence of smooth muscle dierentiation and benign clinical behavior were classi®ed as leiomyomas. Tumors that showed histologic and immunohistochemical evidence of smooth muscle dierentiation that displayed malignant clinical behavior were classi®ed as leiomyosarcomas (Franquemont and Frierson, 1992) . Sixteen gastrointestinal stromal tumors were less than 5 cm in greatest dimension, while 24 were at least 5 cm. Five of the eight leiomyomas were less than 5 cm in greatest diameter. Thirty-eight gastrointestinal stromal tumors had less than 10 mitotic ®gures per 50 high power ®elds, while eight neoplasms had at least ten mitotic ®gures per 50 high power ®elds (Franquemont and Frierson, 1992) .
McIntire Tumor Registry records and hospital charts were reviewed for tumor behavior and patient follow-up. Gastrointestinal stromal tumors were classi®ed as malignant based exclusively on their clinical behavior. Those that invaded adjacent structures (retroperitoneum or other organs), had uncontrollable local disease, or metastasized were classi®ed as malignant. Twenty-one patients had malignant neoplasms, while 13 showed no evidence of malignant clinical behavior. The follow-up for the 13 patients (one patient had two tumors) whose tumors lacked malignant clinical behavior ranged from 5 ± 41 years (median 7 years). Follow-up was not adequate for 11 patients with tumors that did not ful®ll criteria initially for unequivocal malignancy.
Immunohistochemistry
One representative block from each tumor was sectioned for immunohistochemistry. Sections were deparanized, rehydrated, and blocked with methanolic 3% hydrogen peroxide. Primary antibodies used included those to desmin (clone 33, pre-diluted, BioGenex, Dublin, CA, USA), CD34 (clone My10, 1 : 20 dilution, Becton Dickinson, San Jose, CA, USA), and KIT (polyclonal, 1 : 250 dilution, Research Diagnostics Inc., Flanders, NJ, USA). The polyclonal antibody to KIT was directed against amino acid residues 958 ± 76 at the carboxy terminal domain of human KIT p145. Epitope retrieval was used only for the antibody to KIT; the slide was human KIT p145. Epitope retrieval was used only for the antibody to KIT; the slide c-kit mutation in GISTs CA Moskaluk et al was immersed in 10 mM citrate buer, pH 6.0 and heated in a microwave oven at a high setting (Emerson, 1200 W). Evaporated liquid was replenished at 5 min intervals for a total of 20 min. Staining for desmin was performed manually, while that for CD34 and KIT was performed on an automated immunostainer (Ventana ES, Ventana Medical Systems Inc., Tucson, AZ, USA). Using the automated procedure for KIT, endogenous biotin activity was blocked by adding avidin and biotin blocking reagents (supplied by Ventana). The avidin-biotin-peroxidase staining technique was used followed by incubation with 3,3'-diaminobenzidine tetrahydrochloride and counterstaining with hematoxylin. Appropriate positive and negative controls were employed. In normal control tissues, the KIT antibody stained only interstitial cells of Cajal and mast cells, as described in previous reports.
DNA extraction
Seven um histologic sections were cut from archival formalin-®xed paran-embedded tumors or frozen tumors, and were placed on plain glass slides. The sections were stained with H&E and rehydrated in a buer solution containing 2.5% glycerol, as described previously (Moskaluk and Kern, 1997). Tumor and benign tissue were dissected separately, using a scalpel under direct microscopic visualization. Tumor samples were collected that contained less than 10% non-neoplastic cells. The tissues were digested with proteinase K, then treated with Chelex resin and subjected to heat inactivation as described previously (Moskaluk and Kern, 1997) .
Polymerase chain reaction
In an initial study, PCR primers were designed from the c-DNA sequence of the c-kit gene to¯ank the consensus area of mutation in the JM domain of exon 11 (Hirota et al., 1998; Vandenbark et al., 1992) . (5'-CTGGCAT-GATGTGCATTATTG-3', 5'-CAAAACTCAGCCTGTT-TCTG-3', the PCR product is 257 bp and ampli®es intron 10 as well as the majority of exon 11). After our initial survey, a new set of PCR primers was designed on intronic sequences¯anking exon 11, to rule out the possibility of ampli®cation of pseudogenes or homologous genes (5'-ATTATTAAAAGGTGATCTATTTTT-3', 5'-ACTGT-TATGTGTACCCAAAAAG-3', the PCR product is 219 bp long). PCR was carried out with the following conditions in a thermocycler (Touchdown, Hybaid Ltd.) under tube thermistor temperature control: 50 ml total reaction volume, with 16RDA buer (Lisitysn et al., 1993) , 2 mM MgCl 2 , 0.4 mM dNTPs, 1 mM primers, 10% DMSO. Fifty to 100 cell equivalents of genomic DNA were used per reaction. Cycling conditions were as follows: 988C for 2 min, hold temperature of 788C at which time 2.5 units Taq polymerase (Gibco BRL) were added, then 40 cycles of 958C for 30 s, 558C for 30 s, 728C for 3 s, followed by one cycle of 72 for 5 min. A negative control (no DNA) was included with each PCR run to monitor for contamination. PCR products were visualized by gel electrophoresis in 2% agarose prior to sequence analysis.
DNA sequencing
PCR products were prepared for cycle sequencing by the addition of 1 ml of 10 m/ml Exonuclease I (USB/Amersham Life Sciences), a 378C incubation for 15 min, followed by the addition of 5 ml of 1 m/ml shrimp alkaline phosphatase (Boehringer Mannheim), a 378C incubation for 30 min, followed by a 808C incubation for 15 min. The PCR products were then sequenced using a 32 P-endlabeled primer and the EXCEL II cycle sequencing kit (Epicentre Technologies) by the protocol supplied by the manufacturer. The sequencing primer used for PCR #1 was: 5'-ATGTGCATTATTGTGATGATTC-3' (sense strand). The sequencing primer used for PCR #2 was: 5'-TGTGTACC-CAAAAAGGTGACATGG-3' (anti-sense strand). Cycling conditions were as follows: 30 cycles of 30 s at 948C, 30 s at 558C, 1 min at 708C.
Veri®cation of mutations
All mutations were con®rmed by a second independent round of PCR and cycle sequencing. Samples of normal tissue were subjected to PCR and sequencing in order to determine if changes from wild-type DNA sequence detected in tumors were germline or somatic in nature.
